Corteva (CTVA) investor relations material

Strategic direction and innovation

• Transitioned to a pure-play crop protection company with a balanced, diversified portfolio, generating 65% of revenue from differentiated or patented products and leveraging market-leading innovation platforms.

• Innovation pipeline valued at ~$11B, targeting 12 new actives (including 5 biologicals) to launch over the next decade, aiming for $4B in peak revenue.

• Commercial model emphasizes differentiated technology, tailored go-to-market strategies, deep customer insight, and AI-driven tools to accelerate adoption and maximize value.

• External innovation through partnerships, acquisitions, in-licensing, and $93M invested in startups since 2023 complements internal R&D and expands capabilities.

• Disciplined capital allocation prioritizes high-return growth, innovation, shareholder returns, and maintaining an investment-grade balance sheet.

Financial guidance and performance

• Revenue projected to grow from $7.8B in 2026 to $8.4–$8.7B by 2029, a 3% CAGR, with operating EBITDA rising from $1.3B in 2026 to $1.45–$1.65B in 2029 at a 6% CAGR and margins surpassing 18%.

• Operating EBITDA margin to improve by ~250 bps, reaching ~18% by 2026, with further gains to high-teens by 2029.

• Cumulative cash flow from operations forecasted at $2.2–$2.6B through 2029, supporting reinvestment, dividends, targeted M&A, and share repurchases.

• Productivity initiatives to deliver $500M in recurring savings by 2029, with $200M incremental to prior targets, requiring no new capital.

• New products and biologicals expected to drive ~$800M in incremental sales and ~$450M in incremental EBITDA by 2029.

Innovation and pipeline development

• Differentiated R&D platforms, including AI-powered discovery and predictive safety, accelerate innovation and improve success rates.

• Pipeline includes next-generation fungicides, insecticides, herbicides, and plant performance products, with major launches such as Haviza, Varpelgo, and Utrisha N.

• R&D efficiency exceeds 2x competitor average, with pipeline value per R&D dollar at 22.6x.